Genetic variability and population diversity of the human SLCO (OATP) transporter family

DeGorter, 2012, Drug transporters in drug efficacy and toxicity, Annu. Rev. Pharmacol. Toxicol., 52, 249, 10.1146/annurev-pharmtox-010611-134529 Hsiang, 1999, A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters, J. Biol. Chem., 274, 37161, 10.1074/jbc.274.52.37161 Simonson, 2004, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine, Clin. Pharmacol. Ther., 76, 167, 10.1016/j.clpt.2004.03.010 Kameyama, 2005, Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells, Pharmacogenet. Genomics, 15, 513, 10.1097/01.fpc.0000170913.73780.5f Nakagomi-Hagihara, 2006, OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker, Drug Metab. Dispos., 34, 862, 10.1124/dmd.105.008888 Yamashiro, 2006, Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans, Drug Metab. Dispos., 34, 1247, 10.1124/dmd.105.008938 Treiber, 2007, Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil, Drug Metab. Dispos., 35, 1400, 10.1124/dmd.106.013615 Roth, 2012, OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies, Br. J. Pharmacol., 165, 1260, 10.1111/j.1476-5381.2011.01724.x Hagenbuch, 2013, The SLCO (former SLC21) superfamily of transporters, Mol. Aspects Med., 34, 396, 10.1016/j.mam.2012.10.009 Tachikawa, 2018, Liver zonation index of drug transporter and metabolizing enzyme protein expressions in mouse liver acinus, Drug Metab. Dispos., 46, 610, 10.1124/dmd.117.079244 König, 2000, Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide, J. Biol. Chem., 275, 23161, 10.1074/jbc.M001448200 Gao, 2000, Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier, J. Pharmacol. Exp. Ther., 294, 73 Glaeser, 2007, Intestinal drug transporter expression and the impact of grapefruit juice in humans, Clin. Pharmacol. Ther., 81, 362, 10.1038/sj.clpt.6100056 Li, 2000, Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione, Mol. Pharmacol., 58, 335, 10.1124/mol.58.2.335 Leuthold, 2009, Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters., American journal of physiology, Cell Physiol., 296, C570, 10.1152/ajpcell.00436.2008 Pasanen, 2006, SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid, Pharmacogenet. Genomics, 16, 873, 10.1097/01.fpc.0000230416.82349.90 Pasanen, 2007, Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin, Clin. Pharmacol. Ther., 82, 726, 10.1038/sj.clpt.6100220 SEARCH Collaborative Group, 2008, SLCO1B1 variants and statin-induced myopathy--a genomewide study, N. Engl. J. Med., 359, 789, 10.1056/NEJMoa0801936 Kozyra, 2017, Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response, Genet. Med., 19, 20, 10.1038/gim.2016.33 Bush, 2016, Genetic variation among 82 pharmacogenes: the PGRNseq data from the eMERGE network, Clin. Pharmacol. Ther., 100, 160, 10.1002/cpt.350 Ingelman-Sundberg, 2018, Integrating rare genetic variants into pharmacogenetic drug response predictions, Hum. Genomics, 12, 26, 10.1186/s40246-018-0157-3 Gordon, 2014, Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset, Hum. Mol. Genet., 23, 1957, 10.1093/hmg/ddt588 Fujikura, 2015, Genetic variation in the human cytochrome P450 supergene family, Pharmacogenet. Genomics, 25, 584, 10.1097/FPC.0000000000000172 Santos, 2018, Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics, Genet. Med., 20, 622, 10.1038/gim.2017.156 Machiela, 2015, LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants, Bioinformatics, 31, 3555, 10.1093/bioinformatics/btv402 Chun, 2009, Identification of deleterious mutations within three human genomes, Genome Res., 19, 1553, 10.1101/gr.092619.109 Reva, 2011, Predicting the functional impact of protein mutations: application to cancer genomics, Nucleic Acids Res., 39, e118, 10.1093/nar/gkr407 Choi, 2012, Predicting the functional effect of amino acid substitutions and indels, PLoS One, 7, 10.1371/journal.pone.0046688 Carter, 2013, Identifying Mendelian disease genes with the variant effect scoring tool, BMC Genomics, 14, S3, 10.1186/1471-2164-14-S3-S3 Kircher, 2014, A general framework for estimating the relative pathogenicity of human genetic variants, Nat. Rev. Clin. Oncol., 46, 310 Wang, 2010, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data, Nucleic Acids Res., 38, 10.1093/nar/gkq603 Zhou, 2018, An optimized prediction framework to assess the functional impact of pharmacogenetic variants, Pharmacogenomics J. Kelley, 2015, The Phyre2 web portal for protein modeling, prediction and analysis, Nat. Protoc., 10, 845, 10.1038/nprot.2015.053 Lee, 2005, Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry, J. Biol. Chem., 280, 9610, 10.1074/jbc.M411092200 Zhou, 2013, Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2, AAPS J., 15, 1099, 10.1208/s12248-013-9515-1 Niemi, 2011, Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake, Pharmacol. Rev., 63, 157, 10.1124/pr.110.002857 Michalski, 2002, A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter, J. Biol. Chem., 277, 43058, 10.1074/jbc.M207735200 Mwinyi, 2004, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics, Clin. Pharmacol. Ther., 75, 415, 10.1016/j.clpt.2003.12.016 Tirona, 2001, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans, J. Biol. Chem., 276, 35669, 10.1074/jbc.M103792200 Iwai, 2004, Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C), Pharmacogenetics, 14, 749, 10.1097/00008571-200411000-00006 Nozawa, 2005, Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms, Drug Metab. Dispos., 33, 434, 10.1124/dmd.104.001909 Katz, 2006, Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics, Clin. Pharmacol. Ther., 79, 186, 10.1016/j.clpt.2005.11.003 Tirona, 2003, Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation, J. Pharmacol. Exp. Ther., 304, 223, 10.1124/jpet.102.043026 Oswald, 2008, Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1, Pharmacogenet. Genomics, 18, 559, 10.1097/FPC.0b013e3282fe9a2c Smith, 2007, Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics, Clin. Pharmacol. Ther., 81, 76, 10.1038/sj.clpt.6100011 Schwarz, 2011, Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity, Pharmacogenet. Genomics, 21, 103, 10.1097/FPC.0b013e328342f5b1 Picard, 2010, The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics, Clin. Pharmacol. Ther., 87, 100, 10.1038/clpt.2009.205 Chew, 2012, Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients, Br. J. Clin. Pharmacol., 73, 606, 10.1111/j.1365-2125.2011.04123.x Nozawa, 2002, Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis, J. Pharmacol. Exp. Ther., 302, 804, 10.1124/jpet.302.2.804 Imanaga, 2011, The effects of the SLCO2B1 c.1457C&T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans, Pharmacogenet. Genomics, 21, 84, 10.1097/FPC.0b013e32834300cc Ieiri, 2012, Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose, J. Clin. Pharmacol., 52, 1078, 10.1177/0091270011408612 Kashihara, 2017, Small-dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (Atorvastatin and Grapefruit Juice) profiles of 5 probes for OATP2B1 and BCRP, J. Pharm. Sci., 106, 2688, 10.1016/j.xphs.2017.03.010 Mougey, 2009, Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response, Pharmacogenet. Genomics, 19, 129, 10.1097/FPC.0b013e32831bd98c Chang, 2005, Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1, J. Pharmacol. Exp. Ther., 314, 533, 10.1124/jpet.104.082370 Yao, 2012, N-Glycosylation dictates proper processing of organic anion transporting polypeptide 1B1, PLoS One, 7, 10.1371/journal.pone.0052563 Pasanen, 2006, Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population, Eur. J. Clin. Pharmacol., 62, 409, 10.1007/s00228-006-0123-1 Mwinyi, 2008, Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations, Eur. J. Clin. Pharmacol., 64, 257, 10.1007/s00228-007-0409-y Ho, 2008, Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore, Drug Metab. Pharmacokinet., 23, 476, 10.2133/dmpk.23.476 Daka Grapci, 2015, Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans, Balk. J. Med. Genet., 18, 5, 10.1515/bjmg-2015-0001 Pasanen, 2008, Global analysis of genetic variation in SLCO1B1, Pharmacogenomics, 9, 19, 10.2217/14622416.9.1.19 Zhou, 2018, Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews, J. Med. Genet., 55, 617, 10.1136/jmedgenet-2018-105429 Briz, 2002, Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells, Mol. Pharmacol., 61, 853, 10.1124/mol.61.4.853 Badagnani, 2006, Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants, J. Pharmacol. Exp. Ther., 318, 521, 10.1124/jpet.106.104364 Lee, 2005, Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment, Clin. Pharmacol. Ther., 78, 330, 10.1016/j.clpt.2005.06.013 Ho, 2007, Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants, Pharmacogenet. Genomics, 17, 647, 10.1097/FPC.0b013e3280ef698f Birmingham, 2015, Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States, Eur. J. Clin. Pharmacol., 71, 329, 10.1007/s00228-014-1800-0 Soko, 2018, An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T&C and ABCG2 c.421A&C, Pharmacogenomics J., 78, 330 Zhou, 2017, Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects, Clin. Pharmacol. Ther., 102, 688, 10.1002/cpt.690 Kaniwa, 2005, Vol. 33, 458 Y. Zhou, K. Fujikura, S. Mkrtchian, V.M. Lauschke, Computational methods for the pharmacogenetic interpretation of Next Generation Sequencing data, Front. Pharmacol. (In review). Lauschke, 2016, Precision medicine and rare genetic variants, Trends Pharmacol. Sci., 37, 85, 10.1016/j.tips.2015.10.006 Lauschke, 2018, How to consider rare genetic variants in personalized drug therapy, Clin. Pharmacol. Ther., 19, 20